As Chief Operating Officer of Azor Biotek, Lubos Marek, PhD, translates pioneering AI research into a scalable drug discovery platform designing novel small molecules targeting miRNA. As former CEO of Mabro, he advanced immunotherapy for hypoxic tumors into clinical stage and secured the EIT Health Seal of Excellence along with non-dilutive funding from Renew Europe. Drawing on senior leadership roles at Novartis, Takeda, and Alexion, and advanced management training from Harvard Business School, he combines operational, strategic, and deal-making expertise. He is now leading Azor’s European expansion, forging strategic R&D collaborations with leading pharma partners.